• We are sorry, but NCBI web applications do not support your browser and may not function properly. More information
Figure 6 is a forest plot diagram depicting pooled relative risk of continence after drugs for overactive bladder when compared to placebo. The data came analyses from randomized controlled clinical trials that were pooled with random effects. The plot has two columns. The left-hand column lists the last name of the drug and the number of examined subjects for the following drugs: Fesoterodine 2,465 subjects; Oxybutynin 922 subjects; Propiverine 691 subjects; Solifenacin 6,304 subjects; Tolterodine 3,404 subjects; and Trospium 2,677 subjects. The right-hand column is a plot of relative risk of continence after each drug when compared to placebo. Each estimate is presented with 95% CI. Mean relative risk is presented by a black dot incorporating confidence intervals represented by horizontal lines. The figure demonstrates that all tested drugs increased continence when compared to placebo. The relative risk of continence was 1.28 (95% CI 1.07, 1.53) for fesoterodine; 1.68 (95% CI 1.32, 2.13) for oxybutynin; 1.44 (95% CI 1.20, 1.73) for propiverine; 1.45 95% CI 1.35, 1.56) for solifenacin; 1.21 (95% CI 1.07, 1.37) for tolterodine; and 1.71 (95% CI 1.47, 1.97) for trospium. Indirect comparison indicated that the differences across the drugs were not significant. Trospium was the most effective to resolve UI.

Figure 6Continence with drugs for overactive bladder when compared to placebo (pooled with random effects estimates from head-to-head RCTs)

From: Results

Cover of Nonsurgical Treatments for Urinary Incontinence in Adult Women: Diagnosis and Comparative Effectiveness
Nonsurgical Treatments for Urinary Incontinence in Adult Women: Diagnosis and Comparative Effectiveness [Internet].
Comparative Effectiveness Reviews, No. 36.
Shamliyan T, Wyman J, Kane RL.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.